Application of imiquimod/dinitrofluorobenzene double drug-carrying nano carrier

A technology of dinitrofluorobenzene bis and drug-loading nanometers, which is applied in the fields of drug devices, active ingredients of nitro compounds, and medical preparations of non-active ingredients, etc., can solve the problems of limited therapeutic effect and low skin concentration, and achieves Good safety, short effect time, and long-lasting effect of the drug

Inactive Publication Date: 2018-02-06
FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as a substrate of P-glyprotein (P-gp), IMQD is still affected by the efflux of P-gp after entering the skin, resulting in a low skin concentration, which limits its therapeutic effect in imiquimod skin immunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of imiquimod/dinitrofluorobenzene double drug-carrying nano carrier
  • Application of imiquimod/dinitrofluorobenzene double drug-carrying nano carrier
  • Application of imiquimod/dinitrofluorobenzene double drug-carrying nano carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1. Application of imiquimod / dinitrofluorobenzene dual drug-loaded nanocarriers in the treatment of skin melanoma

[0024] The preparation of imiquimod / dinitrofluorobenzene dual drug-loaded nanoparticles: Weigh 1mg IMQD and 40mg mPEG-PLGA and dissolve them in ethyl acetate (10ml) to form an organic phase, weigh 5mg DNP and dissolve them in water ( The dosage is 100ml) to form the inner water phase, take 1mg PVA and dissolve it in water (100ml) to form the outer water phase (adjust the pH to 9.0), weigh 2mg PVA and dissolve it in 100ml water to form the dispersed phase. The inner aqueous phase was added to the organic phase to obtain colostrum by ultrasonication, and the colostrum was quickly added to the outer aqueous phase to obtain double emulsion by ultrasonication, and the double emulsion was added dropwise to the dispersed phase and stirred to obtain IMQD / DNP-NPs (i.e. Quimod / Dinitrofluorobenzene dual drug-loaded nanocarrier).

[0025] application:

[0026...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
absorbanceaaaaaaaaaa
Login to view more

Abstract

The invention discloses an application of an imiquimod / dinitrofluorobenzene double drug-carrying nano carrier. The invention provides an application of the imiquimod / dinitrofluorobenzene double drug-carrying nano carrier in preparing a drug for treating cutaneous malignant melanoma. The administration route of the imiquimod / dinitrofluorobenzene double drug-carrying nano carrier is delivered by means of an ultrasonic conductometer in a targeted mode. The imiquimod / dinitrofluorobenzene double drug-carrying nano carrier disclosed by the invention improves the curative effect on malignant melanoma, improves the living quality of patients and prolongs the lifetime.

Description

technical field [0001] The invention relates to the application of imiquimod / dinitrofluorobenzene dual drug-loaded nanocarriers, belonging to the field of drugs for treating tumors. Background technique [0002] Malignant melanoma (referred to as evil melanoma) originates from neural crest cells, accounts for about 1.5% of all tumors, and is the most deadly malignant skin tumor. 21% of patients with metastatic cutaneous malignant melanoma had local skin metastases at the beginning, and 50% of patients had regional lymph node metastases. The prognosis of patients with distant dissemination of melanoma (stage IV) is worse, with a median survival period of 5-8 months and a long-term survival rate of less than 2% over 5 years. In recent years, with the development of my country's social economy, the incidence of malignant melanoma has been increasing year by year, and it has become one of the fastest growing incidences of all malignant tumors in my country. The disease has a h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4745A61K31/04A61K47/34A61K47/32A61P35/00A61M37/00
CPCA61K31/04A61K31/4745A61K47/32A61K47/34A61M37/00A61M2037/0007A61K2300/00
Inventor 杜楠李晓松宋林萍
Owner FIRST HOSPITAL AFFILIATED TO GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products